Bluejay Diagnostics (NASDAQ:BJDX) Trading 0.1% Higher – What’s Next?

Shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) were up 0.1% during trading on Wednesday . The company traded as high as $0.7215 and last traded at $0.7006. Approximately 101,040 shares changed hands during trading, a decline of 19% from the average daily volume of 124,647 shares. The stock had previously closed at $0.7001.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Wall Street Zen raised shares of Bluejay Diagnostics to a “sell” rating in a research note on Saturday, November 1st. Weiss Ratings reissued a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Bluejay Diagnostics Stock Performance

The company has a market cap of $1.27 million, a PE ratio of -0.01 and a beta of 0.65. The firm’s 50 day moving average is $0.97 and its 200-day moving average is $1.47.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its earnings results on Friday, November 7th. The company reported ($1.01) earnings per share for the quarter.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.